SEC Form 4 · accession 0001209191-16-128063

ALDER BIOPHARMACEUTICALS INC · ALDR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Mark James Litton

Officer — Chief Business Officer

Period of report

Jun 13, 2016

Accepted (ET)

Jun 15, 2016 · 7:02 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001423824

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 13, 2016	S	1,900	$28.8963	D	28,100	I	Held in trust for the benefit of Reporting Person's minor child
Common Stock^F1	Jun 13, 2016	S	100	$29.60	D	28,000	I	Held in trust for the benefit of Reporting Person's minor child
Common Stock^F1,F3	Jun 13, 2016	S	1,900	$28.8948	D	28,100	I	Held in trust for the benefit of Reporting Person's minor child
Common Stock^F1	Jun 13, 2016	S	100	$29.60	D	28,000	I	Held in trust for the benefit of Reporting Person's minor child
Common Stock^F1,F4	Jun 13, 2016	S	1,800	$28.8958	D	28,200	I	Held in trust for the benefit of Reporting Person's minor child
Common Stock^F1,F5	Jun 13, 2016	S	200	$29.64	D	28,000	I	Held in trust for the benefit of Reporting Person's minor child
Common Stock	holding	—	—		—	74,567	D

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three trusts for the benefit of Reporting Person's minor children.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.45 to $29.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 to $29.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.45 to $29.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $29.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.